Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Cost of Revenue: 2011-2025

Historic Cost of Revenue for Adma Biologics (ADMA) over the last 12 years, with Sep 2025 value amounting to $58.6 million.

  • Adma Biologics' Cost of Revenue fell 2.63% to $58.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $221.3 million, marking a year-over-year increase of 13.18%. This contributed to the annual value of $206.9 million for FY2024, which is 22.23% up from last year.
  • Adma Biologics' Cost of Revenue amounted to $58.6 million in Q3 2025, which was up 7.01% from $54.8 million recorded in Q2 2025.
  • Adma Biologics' 5-year Cost of Revenue high stood at $60.2 million for Q3 2024, and its period low was $700,000 during Q2 2023.
  • For the 3-year period, Adma Biologics' Cost of Revenue averaged around $45.5 million, with its median value being $49.7 million (2024).
  • Per our database at Business Quant, Adma Biologics' Cost of Revenue plummeted by 97.32% in 2023 and then soared by 7,005.43% in 2024.
  • Adma Biologics' Cost of Revenue (Quarterly) stood at $22.9 million in 2021, then skyrocketed by 56.54% to $35.8 million in 2022, then grew by 19.59% to $42.8 million in 2023, then climbed by 26.62% to $54.2 million in 2024, then dropped by 2.63% to $58.6 million in 2025.
  • Its Cost of Revenue stands at $58.6 million for Q3 2025, versus $54.8 million for Q2 2025 and $53.7 million for Q1 2025.